Early Administration of Methylene Blue Attenuates Mitochondrial Dysfunction and Cognitive Deficits in a Model of Huntington’s Disease
Huntington’s disease (HD) is a fatal neurodegenerative disorder marked by progressive motor, cognitive, and psychiatric impairments, for which no disease-modifying therapies exist. Mitochondrial dysfunction is an early feature of HD, highlighting the need to target bioenergetic deficits early. We evaluated the neuropro...